Résumé
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, earlystage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
| langue originale | Anglais |
|---|---|
| Pages (de - à) | 1462-1474 |
| Nombre de pages | 13 |
| journal | Annals of Oncology |
| Volume | 25 |
| Numéro de publication | 8 |
| Les DOIs | |
| état | Publié - 1 janv. 2014 |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: Annals of Oncology, Vol 25, Numéro 8, 01.01.2014, p. 1462-1474.
Résultats de recherche: Contribution à un journal › Article › Revue par des pairs
TY - JOUR
T1 - 2nd ESMO consensus conference on lung cancer
T2 - Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
AU - Vansteenkiste, J.
AU - Crinò, L.
AU - Dooms, C.
AU - Douillard, J. Y.
AU - Faivre-Finn, C.
AU - Lim, E.
AU - Rocco, G.
AU - Senan, S.
AU - van Schil, P.
AU - Veronesi, G.
AU - Stahel, R.
AU - Peters, S.
AU - Felip, E.
AU - Kerr, Keith
AU - Besse, Benjamin
AU - Eberhardt, Wilfried
AU - Edelman, Martin
AU - Mok, Tony
AU - O'Byrne, Ken
AU - Novello, Silvia
AU - Bubendorf, Lukas
AU - Marchetti, Antonio
AU - Baas, Paul
AU - Reck, Martin
AU - Syrigos, Konstantinos
AU - Paz-Ares, Luis
AU - Smit, Egbert F.
AU - Meldgaard, Peter
AU - Adjei, Alex
AU - Nicolson, Marianne
AU - Weder, Walter
AU - de Ruysscher, Dirk
AU - Le Pechoux, Cecile
AU - de Leyn, Paul
AU - Westeel, Virginie
N1 - Funding Information: RS has reported consultancy/honoraria: Abbott, Amgen, Astellas, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Genentech, Eli Lilly, Roche. EF has reported Consultancy/ honoraria: Lilly, GlaxoSmithKline, Pfizer, Roche, Boehringer Ingelheim. SP has reported Consultancy/honoraria: Roche, Eli Lilly, AstraZeneca, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono, Daiichi-Sankyo, Tesaro. KK has reported Speakers’ bureau: Abbott Diagnostics, Roche, AstraZeneca, Eli Lilly, Pfizer. BB has reported Research grants: Pfizer, Roche, Boehringer Ingelheim, AstraZeneca. JV has reported that he is the Eli Lilly Chair in Respiratory Oncology at the Leuven University (research funding) and is the AstraZeneca Chair in Personalised Lung Cancer Care at the Leuven University (research funding). WE has reported Advisory board: GlaxoSmithKline, Amgen, Novartis, Merck, Teva, Roche, AstraZeneca, Lilly, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb; Speakers’ bureau: Roche, AstraZeneca, Lilly, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Amgen, Novartis, Hexal, Merck; research grants: Eli Lilly. ME has reported Advisory board and/or research funding: Genentech, Boehringer Ingelheim, Lilly, Endocyte. PB has reported Research grants: Pfizer. MR has reported Advisory board: Hoffmann-La Roche, Lilly, Pfizer, AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo; Speakers’ honoraria: Hoffmann-La Roche, Lilly, Pfizer, Bristol-Myers Squibb, AstraZeneca, Daiichi-Sankyo. LP-A has reported Scientific advisor/Speakers’ bureau: Lilly, Roche, Pfizer, Merck, Boehringer Ingeheim, Desi pharma, Celgene. PM has reported Speakers’ bureau: Roche. MN has reported Speakers’ bureau: Roche, Lilly, Boehringer Ingelheim, Pfizer, Otsuka; Research grants: Roche, Lilly, Boehringer Ingelheim, Pfizer, Novartis. SS has reported Research grants and honoraria: Varian Medical Systems; member of phase III trial management group conducted by Lilly Oncology. CF-F has reported Research grants AstraZeneca, Eli Lilly. GR has reported Speakers’ bureau/grants: Covidien. EL has reported Research support: ScreenCell and PointHope; previously Speakers’ bureau for Roche and Imedex and Advisory board for Strategen, Abbott Molecular and GlaxoSmithKline; patent pending with Clearbridge BioMedics; stock in Pfizer. VW has reported Consultancy/honoraria: Lilly, Roche, Boehringer Ingelheim and AstraZeneca (for lectures); Advisory role: Lilly, Roche, AstraZeneca; currently conducting research sponsored by Merck Serono. TM has reported Speakers’ bureau and Honoraria from: AstraZeneca, Roche, Eli Lilly, Merck Serono, Eisai, Bristol-Myers Squibb BeiGene, AVEO, Pfizer, Taiho, Boehringer Ingelheim, GlaxoSmithKline Biologicals, Clovis Oncology; research funding from AstraZeneca. LB has reported Speakers’ honoraria: Pfizer, Roche, Abbott Molecular Inc.; research supported by and stock held in Roche. SN, AM, KS, ES, AA, PVS, J-YD, WW, DDR, CLP, PDL, GV and CD have declared no potential conflicts of interest. LC and KO’B have not reported any potential conflicts of interest.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, earlystage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
AB - To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines in advanced disease, earlystage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on early-stage disease.
KW - Consensus
KW - ESMO
KW - Early disease
KW - Lung cancer
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84904545741&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdu089
DO - 10.1093/annonc/mdu089
M3 - Article
C2 - 24562446
AN - SCOPUS:84904545741
SN - 0923-7534
VL - 25
SP - 1462
EP - 1474
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -